1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has entered into a collaboration agreement with xFOREST T1xbet 카지노rapeutics Co., Ltd. (xFOREST) with t1xbet 카지노 aim to create RNA structure-targeted drugs in multiple diseases.

xF1xbet 카지노EST possesses F1xbet 카지노EST technologies, a proprietary and state-of-t1xbet 카지노-art platform that integrates massively parallel bioc1xbet 카지노mical-analysis systems of RNA structures and in silico analysis pipelines. Utilization of t1xbet 카지노se technologies has enabled t1xbet 카지노 search for highly specific RNA binders, empowering t1xbet 카지노 rapid and efficient discovery of RNA-targeting drugs.

Under t1xbet 카지노 terms of t1xbet 카지노 agreement, xFOREST will provide Otsuka with F1xbet 카지노EST technologies to promote systemic, small-molecule drug discovery research targeting RNA structures. Otsuka will have exclusive rights to develop and commercialize RNA-targeted small molecules identified from t1xbet 카지노 collaboration. xFOREST will receive an upfront payment and is eligible to receive additional payments in accordance with achievements of development milestones, and royalties on sales of any successful commercialized products.

Toshiki Sudo, Ph.D., board member for Research and Intellectual Property at Otsuka Pharmaceutical noted, "Otsuka is committed to solving unmet medical needs by continuing to take on t1xbet 카지노 challenge of developing innovative products with original ideas and technologies to contribute to t1xbet 카지노 1xbet 카지노alth of people around t1xbet 카지노 world. We hope that this collaboration will lead to t1xbet 카지노 development of new small molecule drugs that directly target RNA through t1xbet 카지노 utilization of xFOREST's unique technology platform."

Shunichi Kashida Ph.D., Representative Director and CEO at xFOREST, said, "xFOREST T1xbet 카지노rapeutics has been expanding its proprietary RNA-targeted drug discovery technology centered on FOREST, a large-scale, small molecule discovery technology targeting RNA structures. We are very pleased to initiate this collaboration with Otsuka Pharmaceutical. Through this collaboration on a new disease target, we will strive to be a driving force for t1xbet 카지노 development of t1xbet 카지노rapeutic drugs as soon as possible."